A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Given the role of constitutively active Signal Transducer and Activator of Transcription (Stat) 3 in human tumors, Stat3 inhibitors would be useful as novel therapeutics and as tools for probing Stat3-mediated tumor processes. We herein report that a 28-mer peptide, SPI, derived from the Stat3 SH2 domain, replicates Stat3 biochemical properties. Studies show SPI and Stat3 (or Stat3 SH2 domain) bind with similar affinities to known Stat3-binding phosphotyrosine (pY) peptide motifs, including those of the epidermal growth factor receptor (EGFR) and the high-affinity, IL-6R/gp130-derived pY-peptide, GpYLPQTV-NH(2). Consequently, SPI functions as a potent and selective inhibitor of Stat3 SH2 domain:pTyr interactions and disrupts the binding of Stat3 to the IL-6R/gp130 peptide, GpYLPQTV-NH(2). Fluorescence imaging and immunofluorescence staining/laser-scanning confocal microscopy show SPI is cell membrane-permeable, associates with the cytoplasmic tail of EGFR in NIH3T3/hEGFR, and is present in the cytoplasm, but strongly localized at the plasma membrane and in the nucleus in malignant cells harboring persistently active Stat3. Moreover, SPI specifically blocks constitutive Stat3 phosphorylation, DNA binding activity, and transcriptional function in malignant cells, with little or no effect on the induction of Stat1, Stat5, and Erk1/2(MAPK) pathways, or on general pTyr profile at the concentrations that inhibit Stat3 activity. Significantly, treatment with SPI of human breast, pancreatic, prostate, and non-small cell lung cancer cells harboring constitutively active Stat3 induced extensive morphology changes, associated with viability loss and apoptosis. Our study identifies SPI as a novel molecular probe for interrogating Stat3 signaling and that functions as a selective inhibitor of Stat3 activation with antitumor cell effects.
Zhao
Wei
W
Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827, USA.
Jaganathan
Soumya
S
Turkson
James
J
D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002463:Cell Membrane Permeability; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003593:Cytoplasm / Q000378:metabolism; D006801:Humans; D015151:Immunoblotting; D051379:Mice; D018613:Microscopy, Confocal; D008958:Models, Molecular; D008969:Molecular Sequence Data; D041681:NIH 3T3 Cells; D010455:Peptides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D011485:Protein Binding; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D050796:STAT3 Transcription Factor / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D018909:src Homology Domains
D000970:Antineoplastic Agents; D010455:Peptides; D050796:STAT3 Transcription Factor
Mol Cell Biol. 1999 Nov;19(11):7519-28
10523640
Bioorg Med Chem Lett. 2008 Jan 1;18(1):391-5
18006313
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6
17463090
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5
15781862
Nucleic Acids Res. 2003 Jul 1;31(13):3375-80
12824331
ChemMedChem. 2008 Aug;3(8):1159-68
18683176
Expert Opin Investig Drugs. 2009 Jan;18(1):45-56
19053881
J Pharmacol Exp Ther. 2010 May;333(2):373-81
20100905
Chembiochem. 2008 Nov 24;9(17):2800-3
19006150
Mol Cell Biol. 1998 May;18(5):2545-52
9566874
J Comput Chem. 2004 Oct;25(13):1605-12
15264254
J Med Chem. 2005 Oct 20;48(21):6661-70
16220982
Anticancer Drugs. 2006 Jan;17(1):13-20
16317285
Mol Cancer Ther. 2004 Mar;3(3):261-9
15026546
Nature. 1998 Jul 9;394(6689):145-51
9671298
Biochemistry. 1994 May 31;33(21):6490-4
7515682
J Mol Biol. 1997 Apr 4;267(3):727-48
9126849
J Biol Chem. 2001 Nov 30;276(48):45443-55
11579100
J Biol Chem. 2000 Aug 11;275(32):24935-44
10823829
Science. 1995 Jul 7;269(5220):81-3
7541555
Expert Opin Ther Targets. 2004 Oct;8(5):409-22
15469392
EMBO J. 1990 Dec;9(13):4477-84
2176154
Breast Cancer Res. 2000;2(2):86-90
11250696
Nat Rev Cancer. 2002 Oct;2(10):740-9
12360277
ACS Med Chem Lett. 2010 May 13;1(2):85-89
20596242
ACS Chem Biol. 2007 Dec 21;2(12):787-98
18154266
Nat Rev Mol Cell Biol. 2002 Mar;3(3):177-86
11994738
Cell Res. 2008 Feb;18(2):254-67
18227858
Bioorg Med Chem Lett. 1999 Feb 8;9(3):347-52
10091682
Endocrinology. 1995 Dec;136(12):5700-8
7588326
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3041-5
7708771
Mol Cell Biol. 1985 May;5(5):1073-83
2582237
Chem Biol. 2006 Nov;13(11):1235-42
17114005
Bioorg Med Chem Lett. 2003 Feb 24;13(4):633-6
12639546
Biochem Pharmacol. 2010 May 15;79(10):1398-409
20067773
Cell Immunol. 1989 Apr 1;119(2):427-44
2467751
Oncogene. 2000 Dec 27;19(56):6613-26
11426647
Nat Med. 2005 Jun;11(6):595-6
15937466
Nat Rev Cancer. 2004 Feb;4(2):97-105
14964307
Biopolymers. 1998;47(3):243-61
9817027
Oncogene. 2001 May 3;20(20):2499-513
11420660